312 related items for PubMed ID: 25557963
21. Congenital adrenal hyperplasia: lessons from a multinational study.
Frisch H, Waldhauser F, Lebl J, Solyom J, Hargitai G, Kovacs J, Pribilincova Z, Krzisnik C, Battelino T, MEWPE-CAH Study Group.
Horm Res; 2002; 57 Suppl 2():95-101. PubMed ID: 12065936
[Abstract] [Full Text] [Related]
22. Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia.
Claahsen-van der Grinten HL, Noordam K, Borm GF, Otten BJ.
J Clin Endocrinol Metab; 2006 Apr; 91(4):1205-9. PubMed ID: 16464952
[Abstract] [Full Text] [Related]
23. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.
Stikkelbroeck NM, Van't Hof-Grootenboer BA, Hermus AR, Otten BJ, Van't Hof MA.
J Clin Endocrinol Metab; 2003 Aug; 88(8):3525-30. PubMed ID: 12915631
[Abstract] [Full Text] [Related]
24. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia.
Gussinyé M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibáñez L, Yeste D.
Pediatrics; 1997 Oct; 100(4):671-4. PubMed ID: 9310523
[Abstract] [Full Text] [Related]
25. Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China.
Juan L, Huamei M, Zhe S, Yanhong L, Hongshan C, Qiuli C, Jun Z, Song G, Minlian D.
J Pediatr Endocrinol Metab; 2016 Jul 01; 29(7):841-8. PubMed ID: 27054598
[Abstract] [Full Text] [Related]
26. Sodium Chloride Supplementation Is Not Routinely Performed in the Majority of German and Austrian Infants with Classic Salt-Wasting Congenital Adrenal Hyperplasia and Has No Effect on Linear Growth and Hydrocortisone or Fludrocortisone Dose.
Bonfig W, Roehl F, Riedl S, Brämswig J, Richter-Unruh A, Fricke-Otto S, Hübner A, Bettendorf M, Schönau E, Dörr H, Holl RW, Mohnike K.
Horm Res Paediatr; 2018 Jul 01; 89(1):7-12. PubMed ID: 29073619
[Abstract] [Full Text] [Related]
27. Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Trinh L, Nimkarn S, New MI, Lin-Su K.
J Pediatr Endocrinol Metab; 2007 Aug 01; 20(8):883-91. PubMed ID: 17937061
[Abstract] [Full Text] [Related]
28. Growth pattern and final height in 21-hydroxylase deficiency.
Bajpai A, Pandey RM, Kabra M, Menon PS.
Indian Pediatr; 2007 Oct 01; 44(10):771-3. PubMed ID: 17998577
[Abstract] [Full Text] [Related]
29. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens.
Rasat R, Espiner EA, Abbott GD.
N Z Med J; 1995 Aug 11; 108(1005):311-4. PubMed ID: 7644165
[Abstract] [Full Text] [Related]
30. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SM, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM.
Arch Dis Child; 2002 Aug 11; 87(2):139-44. PubMed ID: 12138066
[Abstract] [Full Text] [Related]
31. [Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: final height in 27 patients with the classical form].
Lemos-Marini SH, Guerra-Júnior G, Morcillo AM, Baptista MT, Silva LO, Maciel-Guerra AT.
Arq Bras Endocrinol Metabol; 2005 Dec 11; 49(6):902-7. PubMed ID: 16544012
[Abstract] [Full Text] [Related]
32. [Puberty and adult height in congenital virilizing adrenal hyperplasia (author's transl)].
Himon F, Job JC, Pierson M, Canlorbe P.
Sem Hop; 2005 Dec 11; 57(37-38):1488-93. PubMed ID: 6270813
[Abstract] [Full Text] [Related]
33. Impact of Newborn Screening on Adult Height in Patients With Congenital Adrenal Hyperplasia (CAH).
Hoyer-Kuhn H, Eckert AJ, Binder G, Bonfig W, Dübbers A, Riedl S, Woelfle J, Dörr HG, Holl RW.
J Clin Endocrinol Metab; 2023 Oct 18; 108(11):e1199-e1204. PubMed ID: 37256841
[Abstract] [Full Text] [Related]
34. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia.
Muirhead S, Sellers EA, Guyda H, Canadian Pediatric Endocrine Group.
J Pediatr; 2002 Aug 18; 141(2):247-52. PubMed ID: 12183722
[Abstract] [Full Text] [Related]
35. [Puberty and adult height in congenital virilizing adrenal hyperplasia (author's transl)].
Himon F, Job JC, Pierson M, Canlorbe P.
Ann Pediatr (Paris); 1981 Mar 18; 28(3):187-92. PubMed ID: 7224567
[No Abstract] [Full Text] [Related]
36. Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management.
Pinto G, Tardy V, Trivin C, Thalassinos C, Lortat-Jacob S, Nihoul-Fékété C, Morel Y, Brauner R.
J Clin Endocrinol Metab; 2003 Jun 18; 88(6):2624-33. PubMed ID: 12788866
[Abstract] [Full Text] [Related]
37. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
Ciaccio M, Montiveros C, Rivarola MA, Belgorosky A.
Medicina (B Aires); 2002 Jun 18; 62(6):551-4. PubMed ID: 12532689
[Abstract] [Full Text] [Related]
38. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height.
Weintrob N, Dickerman Z, Sprecher E, Galatzer A, Pertzelan A.
Eur J Endocrinol; 1997 Feb 18; 136(2):188-95. PubMed ID: 9116914
[Abstract] [Full Text] [Related]
39. Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond.
Troger T, Sommer G, Lang-Muritano M, Konrad D, Kuhlmann B, Zumsteg U, Flück CE.
J Clin Endocrinol Metab; 2022 Jan 18; 107(2):e487-e499. PubMed ID: 34599587
[Abstract] [Full Text] [Related]
40. [Adult height, pattern of growth and pubertal development in patients with congenital adrenal hyperplasia, salt losing form].
Gussinyé M, Potau N, Vicens-Calvet E, Albisu MA, Yeste D, Ibáñez L, Audí L, Carrascosa A.
Med Clin (Barc); 1997 Jan 25; 108(3):87-90. PubMed ID: 9064437
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
